Kamala Harris

Joe Biden

Dean Phillips

Marianne Williamson

Donald Trump

Vivek Ramaswamy

Nikki Haley

Ron DeSantis

Cornel West

Robert F. Kennedy

2024 United States Presidential Election

Optune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer (NSCLC) that has not responded to platinum-based treatment.

ajmc.com

FDA Approves Optune Lua Device in NSCLC

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in patients with metastatic non–small cell lung cancer.

targetedonc.com

FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC

On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.   Optune Lua is a non-invasive, wearable device that delivers electric fields known as Tumor Treating Fields (TTFields) to …

go2.org

FDA Approves the Wearable Optune Lua Device for Metastatic NSCLC - GO2 for Lung Cancer

FDA Approves Optune Lua Device in NSCLC

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics